Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Modulation Therapy in Pompe Disease
NCT02525172Phase 4Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Aug 2015
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies, Modified Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab, bortezomib, methotrexate, intravenous immunoglobulin G in Pompe disease, sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
rituximabbortezomibmethotrexateintravenous immunoglobulin G
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT02525172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525172.